Belvedere Trading’s Damora Therapeutics DMRA Stock Holding History

Belvedere Trading’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-601	Closed	-$37.9K	–	760
2023 Q2	$37.9K	Buy	+601	New	+$32.7K	﹤0.01%	578

Other funds holding DMRA

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 107.05% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Belvedere Trading's DMRA Position: Q3 2023 in Review

Belvedere Trading sold out of Damora Therapeutics (DMRA) in Q3 2023, closing a stake of 601 shares — an estimated $37.9K sold.

Belvedere Trading first reported a position in DMRA in Q2 2023 and held it in 1 quarter. The position peaked at $37.9K in Q2 2023. 21 funds tracked by Wall St. Rank hold DMRA as of Q3 2023.

Belvedere Trading reported no remaining Damora Therapeutics position as of Q3 2023 after selling out during the quarter.
Belvedere Trading sold 601 Damora Therapeutics shares in Q3 2023, an estimated $37.9K.
Belvedere Trading first reported a position in Damora Therapeutics in Q2 2023 and held it in 1 quarter.
Belvedere Trading's Damora Therapeutics position peaked at $37.9K in Q2 2023.
21 funds tracked by Wall St. Rank held Damora Therapeutics as of Q3 2023.

Based on Belvedere Trading's 13F filing for Q3 2023, filed 27 Oct 2023.